retatrutide clinical trials us Eli Lilly's trial of obesity therapy meets primary endpoint A New Obesity Drug Delivered

Studies in animal colitis models show that BPC-157 may protect the lining of the stomach and intestines and reduce inflammatory damage, supporting mucosal healing in conditions resembling colitis and gastritis

Targeting glioblastoma metabolism with a novel arsenic-based metabolic inhibitor, Penao, in Orange County, CA13118

(2017) 96:897909.e5

For both of these final limitations, the use of rich multimodal clinical data such as clinical notes to assess patient-level features driving motivation for GLP-1 use and discontinuation, as well as imaging to quantify and assess fat loss through CT scans could help shed light on the true impact of GLP-1s on body composition as well as patient profiles that are related to varying levels of treatment effect

Emerging evidence suggests GLP-1 receptor agonists help normalize this balance

It is not the only one